-
Product Insights
NewNet Present Value Model: DICE Therapeutics Inc’s DC-806
Empower your strategies with our Net Present Value Model: DICE Therapeutics Inc's DC-806 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of DICE Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of DICE Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DC-806 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DC-806 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DC-806 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: S-011806 is...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Duvelisib in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Duvelisib in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Duvelisib in Nodal Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Company Profile
Lamb Weston Holdings Inc – Company Profile
Lamb Weston Holdings Inc (Lamb Weston) is a manufacturer and marketer of frozen potato products. The company’s product portfolio comprises fries, sweet potato fries, other potato products and appetizers. Lamb Weston offers products in several varieties, including straight, sliced, diced and mashed. It also sells vegetable and dairy products. The company markets its products under Lamb Weston, Grown in Idaho and Alexia brand names. It distributes products to wholesalers, club retailers, restaurant chains, mass merchants, grocery and specialty retailers, foodservice...
Add to Basket -
Company Profile
DICE Therapeutics Inc – Company Profile
DICE Therapeutics Inc (DICE Therapeutics), formerly DiCE Molecules Holdings LLC, is a pre-clinical stage biopharmaceutical company that develops drugs for the treatment of immunological and chronic diseases. The company is investigating its lead product candidate IL-17 (interleukin 17), an immune-cell-derived cytokine to treat psoriasis and other IL-17 mediated chronic immune disorders and other indications. It is also evaluating drug candidates for the treatment of inflammatory bowel disease, fibrosis and other immune-oncology disorders. The company harnesses its proprietary DELSCAPE platform technology...
Add to Basket -
Company Profile
Netmarble Corp – Company Profile
Netmarble Corp (Netmarble) is a mobile gaming company. It carries out developing various games including Assault Gear, Blossom Party, BTS WORLD, Destiny6, Disney Magical Dice, District 187: Sin Streets, Dragon Ball Online, Dragon Striker, Everybody's Marble, Firstborn: Kingdom Come, Fishing Strike, Grandchase, GunZ: The Duel, Iron Throne, and others. The company's games are supported in android, apple, and others. It's games are used across various regions including the Americas, Europe, Asia-Pacific, Middle East, and Africa. Netmarble is headquartered in Seoul,...
Add to Basket